Lung Cancer: Introduction FeedbackA general introduction to Lung Cancer.Source: NHS Choices, 02 Aug 2013
Lung cancer is one of the most common and serious types of cancer. Over 41,000 people are diagnosed with the condition every year in the UK.
There are usually no signs or symptoms in the early stages of lung cancer, but many people with the condition will eventually develop symptoms including:
- a persistent cough
- coughing up blood
- persistent breathlessness
- unexplained tiredness and weight loss
- an ache or pain when breathing or coughing
You should see your GP if you have these symptoms.
Read more about the symptoms of lung cancer.
Types of lung cancer
Cancer that begins in the lungs is called primary lung cancer. Cancer that begins in another part of the body and spreads to the lungs is known as secondary lung cancer. This page is about primary lung cancer.
There are two main types of primary lung cancer. These are classified by the type of cells in which the cancer starts. They are:
- non-small-cell lung cancer – the most common type, accounting for more than 80% of cases; can be either squamous cell carcinoma, adenocarcinoma or large-cell carcinoma
- small-cell lung cancer – a less common type that usually spreads faster than non-small-cell lung cancer
The type of lung cancer you have will determine which treatments are recommended.
Read more about diagnosing lung cancer.
Who is affected
Lung cancer mainly affects older people. It is rare in people younger than 40, but the rates of lung cancer rise sharply with age. Lung cancer is most commonly diagnosed in people aged 70-74 years.
Although people who have never smoked can develop lung cancer, smoking is the main cause (about 90% of cases). This is because smoking involves regularly inhaling a number of different toxic substances.
Treating lung cancer
The treatment for lung cancer depends on the type of cancer, how far it has spread and how good your general health is.
If the condition is diagnosed early and the cancerous cells are confined to a small area, surgery to remove the affected area of lung is usually recommended.
If surgery is unsuitable due to your general health, radiotherapy to destroy the cancerous cells may be recommended instead.
If the cancer has spread too far for surgery or radiotherapy to be effective, chemotherapy is usually used.
Read more about the treating lung cancer.
As lung cancer does not usually cause noticeable symptoms until it has spread through much of the lungs or into other parts of the body, the outlook for the condition is not as good as many other types of cancer.
Overall, about 1 in 3 people with the condition will live for at least a year after they are diagnosed and fewer than 1 in 10 people will live at least five years.
However, survival rates can vary widely depending on how far the cancer has spread at the time of the diagnosis. Early diagnosis can make a big difference.
Read about living with lung cancer.
Lung Cancer: Guidance FeedbackThe most relevant search results for Lung Cancer from producers of guidance information.
- Scottish Intercollegiate Guidelines Network, 13 February 2014
- National Institute for Health and Care Excellence, 01 April 2011
British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults [PDF]British Thoracic Society, 07 November 2011
- Lung cancer
- Royal College of Radiologists, 01 January 2008
- National Institute for Health and Care Excellence, 19 November 2012
Lung Cancer: Commissioning FeedbackThe most relevant search results for Lung Cancer from producers of commissioning advice.
- National Institute for Health and Care Excellence, 28 April 2012
- National Institute for Health and Care Excellence, 01 March 2012
Information for the public
Lung Cancer: Information for the public FeedbackThe most relevant search results for Lung Cancer, from Department of Health accredited producers of patient information.
- Cancer Research UK, 16 July 2014
- Cancer Research UK, 17 July 2014
- Cancer Research UK, 17 July 2014
- Cancer Research UK, 11 July 2014
- Cancer Research UK, 08 July 2014
- Cancer Research UK, 27 May 2014
- Cancer Research UK, 15 April 2014
- Cancer Research UK, 14 May 2014
- Cancer Research UK, 14 May 2014
- Cancer Research UK, 14 May 2014
Lung Cancer: Ongoing Research FeedbackThe most relevant search results for Lung Cancer, from research trials.
Biomarkers for Early Detection of Lung Cancer in Patients With Lung Cancer, Participants at High-Risk for Developing Lung Cancer, or Healthy VolunteersUK Clinical Trials Gateway, 09 May 2009
Detection in Blood of Autoantibodies to Tumour Antigens as a Case-finding Method in Lung Cancer Using the EarlyCDT-Lung TestUK Clinical Trials Gateway, 15 August 2013
- UK Clinical Trials Gateway, 31 July 2012
Liverpool Lung Project: Risk Factors and Genetic Markers in Healthy Participants and Patients With Lung CancerUK Clinical Trials Gateway, 17 July 2007
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung CancerUK Clinical Trials Gateway, 03 October 2012
- UK Clinical Trials Gateway, 05 March 2009
- UK Clinical Trials Gateway, 27 August 2010
- UK Clinical Trials Gateway, 01 October 2010
The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung CancerUK Clinical Trials Gateway, 04 April 2011
A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsUK Clinical Trials Gateway, 09 July 2013
Lung Cancer: Evidence Uncertainty FeedbackThe most relevant search results for Lung Cancer, highlighting areas where further research is needed.
- UK Database of Uncertainties about the Effects of Treatments, 13 February 2014
Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancerUK Database of Uncertainties about the Effects of Treatments, 16 September 2013
The role of fine needle aspiration biopsy (FNAB) and core needle biopsy (CNB) - alone or in combination - for diagnosing lung cancer in patients with a lung lesionUK Database of Uncertainties about the Effects of Treatments, 11 September 2012
Exercise training undertaken within 12 months following lung resection for patients with non-small cell lung cancerUK Database of Uncertainties about the Effects of Treatments, 20 July 2012
The biologically effective dose of stereotactic body radiotherapy for stage I non-small-cell lung cancerUK Database of Uncertainties about the Effects of Treatments, 11 September 2012
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancerUK Database of Uncertainties about the Effects of Treatments, 20 July 2012
Interobserver variation in the delineation of target volumes using positron emission tomography for non-small cell lung cancer patients with atelectasisUK Database of Uncertainties about the Effects of Treatments, 11 September 2012
- UK Database of Uncertainties about the Effects of Treatments, 01 December 2009
- UK Database of Uncertainties about the Effects of Treatments, 24 September 2009
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseUK Database of Uncertainties about the Effects of Treatments, 04 June 2008
Lung Cancer: Medicines FeedbackAppropriate medicines information for Lung Cancer supplied by Datapharm, a leading source of trusted, credible information about medicines.
Lung cancer - Medicines Information
- Bevacizumab (a generic version of Avastin)
- Bleo-Kyowa (a brand of Bleomycin Sulphate)
- Bleomycin sulphate
- Cyclophosphamide monohydrate
- Doxorubicin hydrochloride
- Doxorubin (a brand of Doxorubicin Hydrochloride)
- Endoxana (a brand of Cyclophosphamide Monohydrate)
- Epirubicin hydrochloride
- Eposin (a brand of Etoposide)
- Erlotinib hydrochloride (a generic version of Tarceva)
- Etoposide phosphate (a generic version of Etopophos)
- Gefitinib (a generic version of Iressa)
- Gemcitabine hydrochloride (a generic version of Gemzar)
- Maxtrex (a brand of Methotrexate)
- Mitomycin-C Kyowa (a brand of Mitomycin)
- Pemetrexed disodium (a generic version of Alimta)
- Pharmorubicin (a brand of Epirubicin Hydrochloride)
- Taxol (a brand of Paclitaxel)
- Taxotere (a brand of Docetaxel)
- Topotecan hydrochloride (a generic version of Hycamtin)
- Vincristine sulphate
- Vinorelbine tartrate
- Results are currently sorted by relevance (Sort results by: date)
- Results 1 - 10 (of 246)
Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk
...anti-inflammatory drug use and lung cancer risk Xu J, Yin Z, Gao W...association between aspirin use and lung cancer risk in cohort and clinical trials...anti-inflammatory drug) use and lung cancer risk with cohort studies (RR 0.93...
Database of Abstracts of Reviews of Effects, 17 July 2012
...cancer sooner Donate HOME ABOUT CANCER Cancer types Breast cancer Bowel cancer Lung cancer Prostate cancer More... Cancers in general What is cancer? Symptoms and screening Tests Treatment Clinical...
Cancer Research UK, 16 July 2014
...Wu 2003; Zhang 2007) Lung cancer Three observational studies...reported data on the risk of lung cancer: one cohort study (Li 2008...2005; Zhong 2001) Oral cancer One cohort study (Ide 2007) reported data on the risk of cancers of oral cancers (cancer of...
Cochrane Database of Systematic Reviews, 08 July 2009 - Publisher: John Wiley & Sons, Ltd
...metastatic or locally advanced lung cancer who received chemotherapy. They...cell (Haas 2005) or small cell lung cancer (Altinbas 2004), or both (Agnelli...versus control: symptomatic VTE in lung cancer Outcome or subgroup title ...
Cochrane Database of Systematic Reviews, 15 February 2012 - Publisher: John Wiley & Sons, Ltd
... NIHR Aspirin use and risk for lung cancer: a meta-analysis Oh SW, Myung...Study Group. Aspirin use and risk for lung cancer: a meta-analysis. Annals...Cohort Studies; Female; Humans; Lung Neoplasms /epidemiology /prevention...
Database of Abstracts of Reviews of Effects, 14 March 2013
...until the patient becomes unconscious. A patient with lung cancer who is in active treatment may be informed about possible benefits from cessation of smoking. To forbid a lung cancer patient in palliative care phase to smoke is pointless...
Finnish Medical Society Duodecim, 22 January 2014
...Clinical features of underlying lung cancer include: Hemoptysis. Weight...management of people with suspected lung cancer, see the CKS topic on Lung cancer...clinical features of underlying lung cancer: There is good evidence from...
Clinical Knowledge Summaries, 01 August 2012
...a subgroup with small cell lung cancer at six but not at 12 months...performing routine tests, extensive cancer screening by tumour markers and imaging scans reveals more cancers.311 The prevalence of cancer in patients presenting with...
Scottish Intercollegiate Guidelines Network, 10 November 2011
...less than 21% in cancers of the brain, lung, oesophagus, pancreas...from pancreatic cancer remains the lowest...survival for all cancers • 1.4.iii One...survival for breast, lung and bowel cancer together; and...of the national lung cancer campaign from July...kidney and bladder cancers (“blood in pee...
11 December 2013 - Publisher: Department of Health - Publication type: Media and commentaries
Consideration of Evidence on Antiemetic Drugs for Nausea and Vomiting Associated with Chemotherapy or Radiation Therapy in Adults
...includes a variety of cancers with breast, colorectal, and lung cancer being the most common...in the treatment of lung cancer. European Journal...including a variety of cancers with breast, colorectal, and lung cancer being the most common...
Agency for Health Research and Quality, 12 January 2011
Searches related to “Lung Cancer”
- Areas of interest
Types of information
Select one or more of the 'type of information' options below to narrow your search
- Care Pathways(1)
- Drug / Medicines Management(11)
- Drug Horizon Scanning(2)
- Drug Prescribing and Safety(12)
- Drug Regulatory and Marketing(1)
- Evidence Summaries(5)
- Health Technology Assessments(37)
- Medicines Current Awareness(2)
- Ongoing Trials(17)
- Patient Information(83)
- Policy and Service Development(6)
- Primary Research(2)
- Systematic Reviews(22)
Start typing a Source name to narrow your search, or select one or more from the list
- Agency for Health Research and Quality - AHRQ (1)
- American College of Gastroenterology(2)
- British Committee for Standards in Haematology - BCSH(3)
- British Nuclear Medicine Society - BNMS (1)
- Cancer Research UK (37)
- Clinical Knowledge Summaries - CKS (11)
- Cochrane Database of Systematic Reviews (18)
- College of Emergency Medicine - CEM(1)
- Database of Abstracts of Reviews of Effects - DARE (4)
- electronic Medicines Compendium - eMC (12)
- European Medicines Agency - EMA(1)
- Finnish Medical Society Duodecim(1)
- Healthcare Quality Improvement Partnership - HQIP (2)
- Healthtalkonline (7)
- Macmillan Cancer Support(2)
- Medicines and Healthcare products Regulatory Agency - MHRA(4)
- National Cancer Institute, USA(1)
- National Institute for Health and Care Excellence - NICE (3)
- National Prescribing Centre - NPC (2)
- NHS Choices(26)
- NHS Employers (1)
- NIHR Horizon Scanning Centre - NIHR HSC (2)
- NIHR Journals Library - Health Technology Assessment(36)
- Patient UK(12)
- Royal College of Anaesthetists (2)
- Royal College of Nursing - RCN (1)
- Royal College of Surgeons - RCS (1)
- Scottish Intercollegiate Guidelines Network - SIGN (6)
Medicines and devices
Start typing a Medicine or device name to narrow your search, or select one or more from the A-Z list
- Alpha tocopherol(11)
- Darbepoetin alfa(11)
- Disodium pamidronate(13)
- Fish oil(25)
- Folic acid(41)
- Folinic acid(37)
- Ibandronic acid(17)
- Influenza vaccine(44)
- Insulin glargine(17)
- Interferon gamma(12)
- Mycophenolate mofetil(56)
- Peginterferon alfa-2a(15)
- Pneumococcal vaccine(13)
- Sodium chloride(41)
- Sodium lactate(10)
- Sodium valproate(14)
- Tranexamic acid(10)
- Trastuzumab emtansine(11)
- Zoledronic acid(54)
- Clear all filters